Related Experiment Video
Updated: Sep 29, 2026
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
Published on: June 18, 2015
Oxytocin inhibits proliferation of human breast cancer cell lines
1Department of Biomedical Sciences and Oncology, University of Turin, Italy.
Abstract:
In this study we show that treatment of MDA-MB231 hormone-independent human breast cancer cells with oxytocin (OT) or with the OT analogue F314 induces significant growth inhibition together with a change in cell phenotype. In MCF7 and T47D human breast cancer cells, OT inhibits oestrogen-induced cell growth. In these same cells, OT administration significantly enhances the inhibitory effect of tamoxifen on cell proliferation. MDA-MB231, MCF7 and T47D cells all express mRNA specific for the OT receptor. These data suggest that it may be possible to inhibit breast cancer growth using OT and OT analogues.
Insights
Oxytocin (OT) and its analogues can inhibit human breast cancer cell growth. This study found that OT significantly reduces proliferation in hormone-independent and estrogen-sensitive breast cancer cells, suggesting potential therapeutic applications.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Hormone-dependent and independent breast cancers present distinct therapeutic challenges.
- Estrogen receptor status significantly influences treatment strategies for breast cancer.
- Oxytocin (OT) is a peptide hormone with known physiological roles, but its direct effects on cancer cells are under investigation.
Purpose of the Study:
- To investigate the effects of oxytocin (OT) and its analogue F314 on the proliferation and phenotype of human breast cancer cells.
- To determine if OT can modulate the efficacy of standard breast cancer therapies like tamoxifen.
- To examine the expression of the oxytocin receptor (OTR) in various breast cancer cell lines.
Main Methods:
- Treatment of MDA-MB231, MCF7, and T47D human breast cancer cell lines with oxytocin (OT) or OT analogue F314.
- Assessment of cell growth inhibition and phenotypic changes.
- Evaluation of OT's effect on estrogen-induced growth and tamoxifen's inhibitory action.
- Analysis of oxytocin receptor (OTR) mRNA expression using specific assays.
Main Results:
- Oxytocin (OT) and analogue F314 significantly inhibited the growth of hormone-independent MDA-MB231 breast cancer cells, altering their phenotype.
- In estrogen-sensitive MCF7 and T47D cells, OT suppressed estrogen-induced proliferation.
- OT administration potentiated the anti-proliferative effects of tamoxifen in MCF7 and T47D cells.
- All tested breast cancer cell lines (MDA-MB231, MCF7, T47D) expressed mRNA specific for the oxytocin receptor (OTR).
Conclusions:
- Oxytocin (OT) and its analogues demonstrate significant anti-cancer activity against human breast cancer cells.
- The oxytocin receptor (OTR) is expressed in breast cancer cells, mediating these effects.
- OT may serve as a potential therapeutic agent or adjuvant therapy to enhance existing treatments like tamoxifen for breast cancer.
